Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
VLT Invesco High Income Trust II
PHT Pioneer High Income Fund, Inc.
BTAL AGFiQ U.S. Market Neutral Anti-Beta Fund
BIGC Bigcommerce Holdings Inc
OP Oceanpal Inc
AMZN Amazon.com Inc
BHR Braemar Hotels & Resorts Inc
X United States Steel Corp
ELV Elevance Health Inc
Go

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Closing Price
$2.37
Day's Change
-0.04 (-1.66%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.40
Day's Low
2.37
Volume
(Light)
Volume:
22,184

10-day average volume:
142,573
22,184

Upcoming Events

XLO's fiscal year ends in December
There are no upcoming events for XLO

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
August 9, 2022Q2 2022 Earnings Release-$0.90-$0.81 to -$0.755--
May 12, 2022Q1 2022 Earnings Release-$0.78-$1.17 to -$0.72--
March 1, 2022Q4 2021 Earnings Release-$0.98-$1.79 to -$0.79--
December 2, 2021Q3 2021 Earnings Release-$21.27-$3.13 to -$0.86--

Past IPOs

DateEvent descriptionAmount of offeringNumber of sharesExpected price range
October 22, 2021Xilio Therapeutics Inc Initial Public Offering$11,700,000735,000$16.00 to $16.00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.